Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 76 results
Author [ Title(Desc)] Type Year
Filters: Author is Nathan, Carl  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Nathan C, Ding A.  2010.  Nonresolving inflammation.. Cell. 140(6):871-82.
Nathan C.  2022.  Nonresolving inflammation redux.. Immunity. 55(4):592-605.
Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Quezada LLopez, Somersan S, Warrier T, Little D, Pingle M et al..  2016.  Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.. J Med Chem. 59(13):6027-44.
O
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Ballinger E, Mosior J, Hartman T, Burns-Huang K, Gold B, Morris R, Goullieux L, Blanc I, Vaubourgeix J, Lagrange S et al..  2019.  Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition.. Science. 363(6426)
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
P
Bryk R, Griffin P, Nathan C.  2000.  Peroxynitrite reductase activity of bacterial peroxiredoxins.. Nature. 407(6801):211-5.
Nathan C.  2002.  Points of control in inflammation.. Nature. 420(6917):846-52.
Nathan C, Calingasan N, Nezezon J, Ding A, M Lucia S, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NSoo et al..  2005.  Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase.. J Exp Med. 202(9):1163-9.
R
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Lupoli TJ, Fay A, Adura C, Glickman MS, Nathan C.  2016.  Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK.. Proc Natl Acad Sci U S A. 113(49):E7947-E7956.
Singh A, Ottavi S, Krieger I, Planck K, Perkowski A, Kaneko T, Davis AM, Suh C, Zhang D, Goullieux L et al..  2024.  Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase.. Sci Adv. 10(11):eadj6406.
Nathan C.  2020.  Resisting antimicrobial resistance.. Nat Rev Microbiol. 18(5):259-260.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
S
Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S et al..  2008.  Selective killing of nonreplicating mycobacteria.. Cell Host Microbe. 3(3):137-45.
Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O et al..  2015.  Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.. Cell Host Microbe. 17(2):178-90.
Mosior J, Bourland R, Soma S, Nathan C, Sacchettini J.  2019.  Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis.. Protein Sci.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
T
Nathan C.  2009.  Taming tuberculosis: a challenge for science and society.. Cell Host Microbe. 5(3):220-4.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C et al..  2003.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment.. J Exp Med. 198(5):693-704.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
V
Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, Ehrt S, Nathan C.  2011.  Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes.. Cell Host Microbe. 9(1):21-31.
W
Nathan C.  2015.  What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev. 264(1):2-5.